DT MedTech announced first U.S. implantations of the Hintermann Series H2® Total Ankle.
The two-component, semi-constrained device can also be used to revise failed ankle replacements or non-union/mal-union of ankle arthrodesis. It is intended for cemented use only in the U.S. Its H2 design is based on the Hintermann H3 mobile-bearing ankle (not for U.S. sale) which has 18 years of positive clinical outcomes. H2 has had >40 implantations in Europe.
The device received FDA 510(k) clearance in 4Q17. Full U.S. product launch of H2 is slated for late 3Q18.
DT MedTech announced first U.S. implantations of the Hintermann Series H2® Total Ankle.
The two-component, semi-constrained device can also be used to revise failed ankle replacements or non-union/mal-union of ankle arthrodesis. It is intended for cemented use only in the U.S. Its H2 design is based on the Hintermann H3 mobile-bearing ankle...
DT MedTech announced first U.S. implantations of the Hintermann Series H2® Total Ankle.
The two-component, semi-constrained device can also be used to revise failed ankle replacements or non-union/mal-union of ankle arthrodesis. It is intended for cemented use only in the U.S. Its H2 design is based on the Hintermann H3 mobile-bearing ankle (not for U.S. sale) which has 18 years of positive clinical outcomes. H2 has had >40 implantations in Europe.
The device received FDA 510(k) clearance in 4Q17. Full U.S. product launch of H2 is slated for late 3Q18.
Copy to clipboard 
